Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intuitive Surgical, Inc. (ISRG) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer headquartered in Sunnyvale, California, Intuitive uses these filings to report financial results, material events, and other information relevant to shareholders and regulators.
Among the key documents available are current reports on Form 8-K. Recent 8-K filings include items reporting quarterly financial results under Item 2.02, where Intuitive furnishes press releases detailing revenue, procedure growth on its da Vinci surgical systems and Ion endoluminal system, and changes in the installed base of systems. Another 8-K filing reports a change in the role of a senior executive under Item 5.02, illustrating how the company discloses updates related to its leadership structure.
Investors also use Intuitive’s SEC filings to follow information that may appear in annual reports on Form 10-K and quarterly reports on Form 10-Q, such as risk factor discussions, descriptions of the company’s business and technologies, and summaries of regulatory and market conditions affecting robotic-assisted surgery and minimally invasive care. While these specific forms are not reproduced in the provided excerpts, they are part of the broader filing set accessible through the SEC’s EDGAR system.
On Stock Titan, ISRG filings are paired with AI-powered summaries designed to explain the content and context of complex documents. These tools can help readers understand the significance of earnings releases, regulatory updates, or governance changes without reading every line of each filing. Users can also review filings that relate to financial reporting, such as exhibits containing press releases, and monitor how Intuitive communicates procedure trends, system placements, and other operational metrics to the market.
For investors researching Intuitive’s regulatory history, this page serves as a focused entry point to the company’s SEC disclosures, including 8-Ks that reference earnings announcements and other material developments.
Intuitive Surgical executive Gary Loeb, EVP & Chief Legal and Compliance, reported several equity-related transactions in company stock. On February 26, 2026, he acquired shares of common stock through the vesting and conversion of previously granted restricted stock units and performance stock units, and also received new equity awards.
The filing shows tax-withholding dispositions of 757 and 455 shares of common stock at $506.17 per share to cover statutory obligations, rather than open-market sales. Loeb was also granted 1,050 performance stock units tied to previously achieved performance metrics and 3,584 new restricted stock units that vest 25% annually over four years.
Intuitive Surgical executive Myriam Curet, EVP & Chief Medical Officer, reported several equity-related transactions in company stock and units. She received a grant of 2,793 performance stock units tied to performance goals that vest on February 28, 2026, three years after the original grant date.
Previously granted restricted stock units were converted into common shares as they vested, including 3,052 and 1,602 RSUs that settled at no cash exercise price. Related common shares are held indirectly by a trust. To satisfy statutory tax withholding, the trust delivered 1,514 and 795 shares at a price of $506.17 per share, with remaining net shares deposited into the holder’s account.
Intuitive Surgical VP Corporate Controller Fredrik Widman reported multiple equity transactions on
To cover statutory tax withholding on the RSU vesting, 303 and 188 shares of common stock were withheld at a price of
INTUITIVE SURGICAL INC director and CEO David J. Rosa reported multiple equity compensation transactions dated February 26, 2026. He acquired 4,788 performance stock units originally granted on February 28, 2023 and 3,018 performance stock units originally granted on June 12, 2023, after performance criteria were certified as achieved. These performance units are scheduled to vest on February 28, 2026, subject to continued service.
Rosa also received a new grant of 13,441 restricted stock units dated February 26, 2026, which vest 25% per year over four years. In addition, 3,816 and 2,289 previously granted restricted stock units were exercised into common stock on a one-for-one basis, with 1,892 and 1,135 common shares respectively withheld at a price of
Intuitive Surgical director Gary S. Guthart reported multiple equity award transactions. He received 8,778 performance stock units granted on February 28, 2023 after performance criteria were achieved, which are scheduled to vest on February 28, 2026, subject to continued service.
He also acquired 4,960 and 3,433 shares of common stock through the vesting and conversion of restricted stock units, with related dispositions of 2,460 and 1,703 shares at $506.17 per share to cover statutory tax withholding obligations. Following these transactions, he holds 9,251 shares of common stock directly, plus additional indirect holdings through family trusts.
Intuitive Surgical senior vice president Mark Brosius reported several equity compensation transactions. He received 2,793 performance stock units originally granted on February 28, 2023, after the company confirmed the required performance goals were achieved. These PSUs are scheduled to vest on February 28, 2026, subject to continued service.
He also received a new grant of 4,928 restricted stock units dated February 26, 2026, which vest 25% annually over four years. Previously granted RSUs from 2024 and 2025 partially vested, converting into 1,622 and 973 shares of common stock, with 805 and 483 shares respectively withheld at a price of $506.17 per share to cover statutory tax obligations.
Intuitive Surgical (ISRG) executive Myriam Curet reported option exercises, RSU vesting, and related share sales through a trust. On February 10, 2026, a trust associated with Curet acquired 838 common shares from vested RSUs and 105 shares via stock option exercise, and disposed of 417 shares to cover taxes. The trust also sold 105 shares at $494.65 on February 10 and 421 shares at $494.96 on February 11 in open-market transactions under a Rule 10b5-1 trading plan. Following these transactions, the trust held 409 common shares, while Curet directly held derivative positions including 1,257 stock options and 838 RSUs subject to the disclosed vesting schedules.
Intuitive Surgical officer Fredrik Widman, VP Corporate Controller, reported several equity transactions around restricted stock unit (RSU) vesting. On February 10, 2026, 567 RSUs converted into an equal number of common shares at an exercise price of $0.0, increasing his directly held common stock to 1,095 shares.
Also on February 10, 302 common shares were disposed of at $492.84 per share to cover statutory tax withholding, leaving 793 common shares directly owned. After these transactions, Widman held 567 RSUs directly.
On February 11, 2026, Widman executed an open‑market sale of 133 common shares at $494.96 per share under a pre‑established Rule 10b5‑1 trading plan that expires on May 21, 2026, resulting in 660 common shares directly owned.
An ISRG shareholder plans to sell 133 common shares under Rule 144 through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned sale has an aggregate market value of
The shares were acquired as restricted stock from the issuer on